Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of BI 730357 on PK of Caffeine, Warfarin, Omeprazole and Midazolam in Healthy Subjects
NCT04679948Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bevurogant in plaque psoriasis, sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of Caffeine in Plasma Over the Time Interval From 0 Extrapolated to Infinity at 48 hours, Maximum Measured Concentration of Caffeine in Plasma at 48 hours and 6 more. Started Dec 2020; status: completed.
02
Drugs
bevurogant
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04679948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04679948.